Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Ferring's degarelix meets prostate cancer endpoint

Ferring (Copenhagen, Denmark) said degarelix met the primary endpoint of

Read the full 104 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE